Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the future of pharmaceutical advertising, health care priorities in the second Trump administration, whether the U.S. will ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

The Food and Drug Administration on Friday cleared Eli Lilly’s obesity drug Zepbound as the first treatment for a common sleep disorder in the U.S. Zepbound, whose scientific name is tirzepatide ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...

Fresh from a $400 million series A round, Kailera Therapeutics has shown off phase 2 data on an obesity candidate it believes can muscle in on the market. Kailera and partner Jiangsu Hengrui ...

Eli Lilly’s weight loss drug Zepbound is no longer in short supply, the FDA said, worrying patients who use cheaper, off-brand versions of the drug. On Thursday, Dec. 19, the U.S. Food and Drug ...